Oric Pharmaceuticals (NASDAQ:ORIC) Rating Increased to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Oric Pharmaceuticals (NASDAQ:ORIC) from a strong sell rating to a sell rating in a report issued on Saturday morning.

Several other equities research analysts also recently issued reports on the company. Stifel Nicolaus initiated coverage on Oric Pharmaceuticals in a research report on Friday, June 12th. They issued a “buy” rating and a $14.00 price target on the stock. Wedbush cut their price objective on Oric Pharmaceuticals from $20.00 to $17.00 and set an “outperform” rating for the company in a research report on Wednesday, April 1st. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of Oric Pharmaceuticals in a research note on Monday, June 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oric Pharmaceuticals in a report on Friday, July 17th. Finally, Benchmark reaffirmed a “buy” rating on shares of Oric Pharmaceuticals in a research report on Monday, June 8th. Thirteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $19.27.

Oric Pharmaceuticals Trading Up 11.1%

NASDAQ ORIC opened at $12.10 on Friday. Oric Pharmaceuticals has a 1 year low of $7.23 and a 1 year high of $14.93. The company has a fifty day simple moving average of $9.39 and a 200 day simple moving average of $10.29. The company has a market cap of $1.25 billion, a P/E ratio of -8.40 and a beta of 1.02.

Oric Pharmaceuticals (NASDAQ:ORIC) last announced its earnings results on Monday, May 4th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.03). Equities research analysts forecast that Oric Pharmaceuticals will post -1.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Oric Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC bought a new position in Oric Pharmaceuticals during the 1st quarter valued at about $276,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Oric Pharmaceuticals by 8.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,201 shares of the company’s stock worth $226,000 after acquiring an additional 3,131 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Oric Pharmaceuticals by 9.2% during the first quarter. Goldman Sachs Group Inc. now owns 294,784 shares of the company’s stock valued at $1,645,000 after acquiring an additional 24,778 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Oric Pharmaceuticals by 1,331.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 509,179 shares of the company’s stock valued at $2,841,000 after acquiring an additional 473,600 shares during the period. Finally, Jane Street Group LLC boosted its holdings in Oric Pharmaceuticals by 56.0% in the first quarter. Jane Street Group LLC now owns 31,198 shares of the company’s stock valued at $174,000 after acquiring an additional 11,198 shares during the last quarter. Institutional investors own 95.05% of the company’s stock.

Oric Pharmaceuticals Company Profile

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.